Latest

From our CEO Mark Lewis: As the year comes to a close, I’ve been taking a moment to reflect on what this year has meant for Myomaker Bio. For those new here Myomaker Bio is a contract research organisation specialising in pre-clinical muscle biology. 2025 has been a whirlwind for us where we: 🎉 Welcomed our first customers🎉 Moved into new offices from Bedford Heights (Thanks Tim King and Investcope Ltd. – was great working with you in the formative stages of Myomaker Bio Ltd.) to LUinc.🎉 Formalised our spin-out from Loughborough University🎉 Took up space in Victoria House –...

The FDA Modernization Act 3.0 is an important step forward for preclinical innovation. By updating regulations to replace references to “animal” testing with broader “nonclinical” language, the Act further enables New Approach Methodologies (#NAMs) such as human-relevant in vitro models and computational tools. This creates regulatory space for approaches that better reflect human biology.The need is clear: many drugs that succeed in animal studies still fail in humans, highlighting the demand for more predictive models. For Myomaker Bio, this shift is especially impactful. NAM-based muscle and neuromuscular models can deliver earlier insight into efficacy and safety and improve translational confidence....

🎉 Exciting Milestone for Our Team! 🎉 Myomaker Bio is excited to announce our move into new premises at Victoria House, London, a space that supports our growing team and expanding scientific capabilities. At Myomaker Bio, we engineer human muscle organs that replicate real muscle structure and function. 🧬 Our Capabilities:• Bespoke Testing Assays• Muscle Function & Morphology• Gene & Protein Expression• Media Analysis Our platforms help partners explore muscle biology across health, exercise, disease, injury and regeneration, from developing therapies for muscle-specific conditions to de-risking off-target effects. We’re thrilled to begin this next chapter in our new home.

We are excited to share the first technical note in our new series exploring how bioengineered human skeletal muscle can be used as a reliable, human-relevant platform to study chemical injury, regeneration, and drug response. Technical Note #1: Barium Chloride (BaCl2): Isomorphic Mimicry Mechanism Key Takeaway of the Series:1. Bioengineered muscle (and neuromuscular) systems reproduce human injury, repair, and pharmacological responsiveness.2. Distinct classes of compounds, injury agents, anabolic nutrients, anti-inflammatory mediators, and metabolic stressors elicit predictable, quantifiable outcomes in tissue function

We are delighted to be part of Axol Biosciences latest technology journal. This showcases our use of axoCellsTM iPSC-derived Motor Neurons as a platform for human neuromuscular junction modeling. Find us on page 20! Download the Journal here: https://hubs.la/Q03SlQHZ0

We’re heading to Liverpool for Drug Discovery 2025!  21–22 October 2025 Liverpool, UK Meet our team in the Breakthrough Zone: Mark Lewis, CEO Dr. Andrew Capel, CSO We’ll be sharing how our assays monitor muscle biology in health, exercise, disease, injury, and regeneration. Let’s talk about how we can support your next breakthrough.